IMPROVING EFFICIENCY AND QUALITY ACROSS THE COMBINATION PRODUCT LIFECYCLE

This exclusive online masterclass has been specifically designed to optimise the end-to-end approach to combination products, from initial design to production and delivery. Recognising the complexity of the product lifecycle, the session offers a toolkit for companies seeking to deliver a joined up approach to therapeutics and device manufacture.

This exclusive masterclass features an exclusive panel led by Dassault Systèmeswhich will examine a digital approach to delivering high quality combination products, cost-effectively and quickly.

Sponsored by Dassault Systèmes

logo image

Meet Our Expert Speakers & Facilitators

Masterclass Agenda - 29th June

BRINGING COMBINATION PRODUCTS TO MARKET - VIRTUALLY ENABLED FOR SPEED, QUALITY AND COST

Exploit digital technologies to meet the complexity and regulatory challenge of combination products.

From design to manufacturing we will be discussing how digital continuity and virtual twins accelerate and improve innovation. We will be looking at and discussing what collaborative design and development can and should look like, we are going to elaborate on the advantages of virtual testing for both devices and therapeutics and we will discuss how manufacturing processes will be designed early in the process with quality and regulatory compliance embedded at every step.

Collaboratively we hope to answer questions such as:

    • What is digital? What does it mean?
    • Why change the way we work? How do I ensure that new technology transforms my organization and improves the way of working?
    • Virtual Testing: What is possible?
    • Virtual Twins: how far can I take virtual testing and simulation? What are the limits?
    • Where do I start? What should I avoid?
Led By: Dr Barbara Holtz, Expert Business Consultant, Life Sciences, Dassault Systèmes

CASE STUDY PRESENTATIONS

Proposed topics include:

    • Improving collaboration between scientists developing therapeutics and engineers developing devices
    • Delivering a joined up approach to usability; building consensus between drug and device development and manufacturing
    • Delivering digital continuity between supply chain partners and across the lifecycle; digitizing existing processes
    • Overcoming barriers to combination product innovation: working with regulators to bring advanced technologies to the patients
    • Managing compliance challenges, such as new regulations like MDR

What Our Past Attendees Have Said: